SMMT Summit Therapeutics Inc.
Healthcare$16.48+0.00%OpenMarket Cap: $12.78B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
31.13
P/S
0.00
EV/EBITDA
-12.09
DCF Value
$0.25
FCF Yield
-2.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-340.6%
ROA
-214.2%
ROIC
-248.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-195.2M | $-189.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-224.9M | $-219.2M | $— | — |
| FY null | $0.00 | NaN% | $-1.09B | $-1.08B | $— | — |
| Q3 null | $0.00 | NaN% | $-234.2M | $-231.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-414.1M | $-412.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-51.7M | $-48.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-52.4M | $-48.9M | $— | — |
| FY null | $0.00 | NaN% | $-180.5M | $-176.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-43.7M | $-42.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-47.2M | $-47.8M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-42.4M | $-43.5M | $— | — |
| Q4 2023 | $-235.0K | 357.4% | $-36.4M | $-36.6M | $-0.05 | — |